Allianz Asset Management
RPTX

Allianz Asset Management’s Repare Therapeutics RPTX Stock Holding History

Allianz Asset Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,270
Closed -$352K – 2276
2020
Q4 		$352K Buy
+10,270
New +$307K ﹤0.01% 1713

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Allianz Asset Management's RPTX Position: Q1 2021 in Review

Allianz Asset Management sold out of Repare Therapeutics (RPTX) in Q1 2021, closing a stake of 10,270 shares — an estimated $352K sold.

Allianz Asset Management first reported a position in RPTX in Q4 2020 and held it in 1 quarter. The position peaked at $352K in Q4 2020. 65 funds tracked by Wall St. Rank hold RPTX as of Q1 2021.

  • Allianz Asset Management reported no remaining Repare Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Allianz Asset Management sold 10,270 Repare Therapeutics shares in Q1 2021, an estimated $352K.
  • Allianz Asset Management first reported a position in Repare Therapeutics in Q4 2020 and held it in 1 quarter.
  • Allianz Asset Management's Repare Therapeutics position peaked at $352K in Q4 2020.
  • 65 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2021.

Based on Allianz Asset Management's 13F filing for Q1 2021, filed 13 May 2021.